House Hopes To Cut FDA Bill Costs With Biosimilars Provision
House lawmakers moved quickly Thursday to prevent a possible roadblock to the U.S. Food and Drug Administration user fee bill, adding a new biosimilars provision that they hoped would cut the...To view the full article, register now.
Already a subscriber? Click here to view full article